Cardiologist

Board certification
Cardiovascular disease, internal medicine and interventional cardiology.

Education
Cardiologist Michael Thurmes, MD, earned his medical degree at the University of Minnesota, Minneapolis, Minn. He completed his cardiology fellowship at Loyola University Medical Center, Ill.

Special medical interests
Transesophageal echo (TEE) and interventional cardiology.

Awards and honors
Named Top Doc in cardiology by Mpls/St Paul magazine, 2006.

For appointments:
952-924-9005

Clinic location
Minnesota Heart Clinic
305 East Nicollet Blvd.
Ridgeview Office Bldg.
Suite 372
Burnsville, MN 55337


Research Experience
Subinvestigator in the following clinical trials:

CARS - Coumadin Aspirin Reinfarction Study (1993-1996)

GUSTO IIb and GUSTO IIB Angiographic Substudy - Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (1994-1996)

GUSTO III - The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Project: A Randomized Trial of Reteplase (r-PA) versus Accelerated Alteplase (t-PA) for the Treatment of Acute Myocardial Infarction (1995-1997)

A Coronary Stent Pilot Study (1996-1997)

InTime-II - Double-blind, Randomized, Multicenter Trial of Single-Bolus Lanoteplase versus Accelerated Alteplase for the Treatment of Subjects with Acute Myocardial Infarction (1997 - 1999)

SYMPHONY Trial - A Phase III, Multicenter, International, Randomized, Double-Blind, Aspirin-controlled Trial to Evaluate the Efficacy and Safety of Sibrafiban (RO48-3657), an Oral Platelet Glycoprotein IIb/IIIa Antagonist, as Therapy for the Prevention of Secondary Vascular Events in Patients after an Acute Coronary Syndrome (1997-1999)

2nd SYMPHONY TRIAL - A Phase III, Multicenter, International, Randomized, Double-Blind, Aspirin-controlled Trial to Evaluate the Efficacy and Safety of Two Regimens with Xubix (sibrafiban;RO48-2657), an Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonist, as Therapy for the Long Term Prevention of Secondary Vascular Events in Patients After an Acute Coronary Syndrome (1998-2000)

ALIVE STUDY - A Double-Blind, Placebo-Controlled, Parallel Design Study to Determine the Effect of 75mg or 100mg of Orally Administered Azimilide Dihydrochloride versus Placebo on Survival in Recent Post-myocardial Infarction Patients at Risk of Sudden Death (1998 - 2001)

AMISTAD II - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Adenosine (Pallacor, Adenosine Injection) as a Adjunct to Reperfusion Therapy (thrombolysis or mechanical reperfusion) in the Treatment of Acute Anterolateral Myocardial Infarction (1999- 2001)

MADIT II Trial – “Multicenter Automatic Defibrillator Implantation Trial II (1999-2002) 

APEX-AMI Study - A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (2004-2006)


back